CN101573149A - Method for preparing an implantable prosthesis from a porous base body and associated prosthesis and use thereof - Google Patents
Method for preparing an implantable prosthesis from a porous base body and associated prosthesis and use thereof Download PDFInfo
- Publication number
- CN101573149A CN101573149A CNA2007800450001A CN200780045000A CN101573149A CN 101573149 A CN101573149 A CN 101573149A CN A2007800450001 A CNA2007800450001 A CN A2007800450001A CN 200780045000 A CN200780045000 A CN 200780045000A CN 101573149 A CN101573149 A CN 101573149A
- Authority
- CN
- China
- Prior art keywords
- cyclodextrin
- coating
- matrix
- prosthese
- bioactivator
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/28—Materials for coating prostheses
- A61L27/34—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/56—Porous materials, e.g. foams or sponges
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/08—Materials for coatings
- A61L31/10—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09D—COATING COMPOSITIONS, e.g. PAINTS, VARNISHES OR LACQUERS; FILLING PASTES; CHEMICAL PAINT OR INK REMOVERS; INKS; CORRECTING FLUIDS; WOODSTAINS; PASTES OR SOLIDS FOR COLOURING OR PRINTING; USE OF MATERIALS THEREFOR
- C09D105/00—Coating compositions based on polysaccharides or on their derivatives, not provided for in groups C09D101/00 or C09D103/00
- C09D105/16—Cyclodextrin; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09D—COATING COMPOSITIONS, e.g. PAINTS, VARNISHES OR LACQUERS; FILLING PASTES; CHEMICAL PAINT OR INK REMOVERS; INKS; CORRECTING FLUIDS; WOODSTAINS; PASTES OR SOLIDS FOR COLOURING OR PRINTING; USE OF MATERIALS THEREFOR
- C09D133/00—Coating compositions based on homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides, or nitriles thereof; Coating compositions based on derivatives of such polymers
- C09D133/02—Homopolymers or copolymers of acids; Metal or ammonium salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/80—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special chemical form
- A61L2300/802—Additives, excipients, e.g. cyclodextrins, fatty acids, surfactants
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
- C08K3/00—Use of inorganic substances as compounding ingredients
- C08K3/32—Phosphorus-containing compounds
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
- C08K5/00—Use of organic ingredients
- C08K5/04—Oxygen-containing compounds
- C08K5/09—Carboxylic acids; Metal salts thereof; Anhydrides thereof
- C08K5/092—Polycarboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L33/00—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides or nitriles thereof; Compositions of derivatives of such polymers
- C08L33/02—Homopolymers or copolymers of acids; Metal or ammonium salts thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
- C08L5/16—Cyclodextrin; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Transplantation (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Surgery (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Materials Engineering (AREA)
- Molecular Biology (AREA)
- Neurosurgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Dispersion Chemistry (AREA)
- Materials For Medical Uses (AREA)
- Prostheses (AREA)
Abstract
The invention relates to a method for preparing an implantable prosthesis from a porous base body and to the associated prosthesis and use thereof. The inventive method comprises the application (50) of a coating (14) to the body (12), said coating being intended to receive a bioactive agent comprising a cyclodextrin and/or a cyclodextrin derivative and/or a cyclodextrin inclusion complex or a poly(carboxylic) acid and a catalyst. The method includes a heating step (58) in which the body (12) is heated to a temperature of between 100 DEG C and 220 DEG C for between 1 and 90 minutes, followed by a step in which the body (12) is washed with water and dried. The method can also include an optional subsequent step in which the body is impregnated in a concentrated solution of at least one bioactive agent.; After the drying step, a sealing coating is deposited on the body (12), after which the body (12) defines an internal sealed liquid flow channel.
Description
The present invention relates to prepare from the matrix (base body) that is made of porous materials the method for implantable prosthesis, this method comprises following consecutive steps:
A) apply the coating that is used to accept bioactivator to matrix, the described coating of accepting comprises:
-at least a cyclodextrin and/or at least a cyclodextrin derivative and/or at least a cyclodextrin inclusion complexes and/or cyclodextrin derivative inclusion complex,
-at least a polycarboxylic acids, and
-optional catalyst;
B) described matrix is heated to 100 ℃-220 ℃ temperature, heated 1-90 minute;
C) the described matrix of washing in water;
D) with described matrix drying; Then
E) randomly, described matrix is immersed in the concentrated solution of at least a bioactivator;
According to an embodiment, the method for preparing implantable prosthesis of the present invention comprises matrix is immersed step e) in the concentrated solution of at least a bioactivator.
" be used to accept the coating of bioactivator " and be meant the coating that to accept at least a bioactivator but must not accept described bioactivator.
It is known making and implant the intravital tubular blood vessel prosthese of the patient who suffers from arterial disease by polyethylene terephthalate.Especially, the purpose of these prostheses is the tremulous pulsies that block or shrink in order to substitute.In this case, use of the bypass of the tubular prostheses of variable-diameter as obstructing arterial.
Such blood vessel prosthesis also is used to avoid aneurysm rupture.Therefore prosthese is inserted in the tremulous pulse in the face of aneurysm, thereby prevents aneurysmal development.
Therefore, implant these prostheses and reduced the mortality in said patients that is subjected to these arterial disease puzzlements to a great extent.
Yet, respectively before the implantation of these prostheses and afterwards because before the art and the postoperative infection risk may develop complications.In order to overcome this defective, application WO 2006/051227 suggestion is constituting coupling collar dextrin on the material that will be placed into the intravital implant of people.Then implant is placed in the bath to load the active ingredient molecule on cyclodextrin, it can be saltoutd after operation in vivo.
Such method is accomplished in laboratory.Yet, unsatisfactory when Zhi Bei implant is in final implant into body by this method, particularly and more generally in robustness, blood compatibility, satisfy in the requirement of law about prosthese unsatisfactory.
Therefore, the purpose of this invention is to provide the method for preparing implantable prosthesis, make to provide and reduce the prosthese that the postoperative infection risk also satisfies the requirement of implant into body simultaneously.
Therefore, the present invention relates to the method for the above-mentioned type, it is characterized in that, this method is included in behind the drying steps step of the other seal coating of on described matrix deposition.
The applicant also finds, even cyclodextrin does not load active ingredient, particularly for example antibiotic, antimicrobial, antiseptic or antitack agent, the cyclodextrin that is attached on the implantable material is unexpectedly given described implantable material bacteriostatic activity even is given its bactericidal activity.
Method of the present invention can be individually or is had one or more following features in the mode of technical feasible combination arbitrarily:
-described seal coating maybe can seal at collagen, gelatin, polyurethanes on the basis of the polymer of described matrix or their combination and form;
-comprise in applying the described step of accepting coating matrix immersed in the aqueous solution that described aqueous solution comprises:
-at least a cyclodextrin and/or at least a cyclodextrin derivative and/or at least a cyclodextrin inclusion complexes and/or cyclodextrin derivative inclusion complex,
-at least a polycarboxylic acids, and
-optional catalyst;
-it is included in before the heating steps under 40 ℃-100 ℃ temperature the step with matrix precuring;
-it is included in the step that drying steps is neutralized to matrix neutral pH afterwards;
-described matrix is by net, textile material or knit materials are made, described net, textile material or knit materials are formed by at least a polymer line, particularly on the basis that is selected from following polymer, form: polyethylene terephthalate (PET), polyethylene terephthalate ethylene glycol (PETG), polyurethanes (PU), polylactic acid, polyglycolic acid and copolymer thereof, polyvinylidene fluoride (PVDF), polytetrafluoroethylene (PTFE), Polyethylene Glycol (PEG), polyamide 6, polyamide 6,6, polypropylene, polyethylene and copolymer thereof, or the combination of these polymer;
-describedly accept the 5%-7% that coating forms described prosthese gross weight;
-optional bioactivator is selected from anticoagulant, antithrombotic agent, antimitotic agent, antiproliferative, antitack agent, anti-migration agent, cell adhesion promoter, somatomedin, anti-parasitic molecule, antiinflammatory, short angiogenic agent, angiogenesis inhibitor, vitamin, hormone, protein, antifungal, antimicrobial molecule, antiseptic and antibiotic; And
-its be included in apply before the step of accepting coating and/or after washing step with the step of matrix embossing (emboss).
-described matrix is a tubular matrix, and the described tubular matrix that provides described coating has defined the liquid circulation channel of sealing in inside.
The invention further relates to implantable prosthesis, it comprises:
-the matrix that is made of porous materials,
-being applied to the coating that is used to accept bioactivator of described matrix, described coating comprises at least a cyclodextrin and/or at least a cyclodextrin derivative and/or at least a cyclodextrin inclusion complexes and/or cyclodextrin derivative inclusion complex,
-randomly, the described at least a bioactivator of accepting to accept in the coating;
It is characterized in that described prosthese comprises the other seal coating that is deposited on the described matrix.
According to an embodiment, implantable prosthesis of the present invention comprises the described at least a bioactivator of accepting to accept in the coating.
The invention still further relates to the application in preparation biocidal property armarium of at least a cyclodextrin and/or at least a cyclodextrin derivative and/or at least a cyclodextrin inclusion complexes and/or cyclodextrin derivative inclusion complex.
According to various variations:
-above-mentioned application is to be used to prepare the bactericidal properties armarium;
-described armarium be used for blood plasma or arbitrarily other biofluid or the tissue contact;
-armarium can implanted at least in part patient's body in;
-described equipment is implantable prosthesis, and it comprises:
-the matrix that is made of porous materials,
-being applied to the coating that is used to accept bioactivator of described matrix, described coating comprises described at least a cyclodextrin and/or at least a cyclodextrin derivative and/or at least a cyclodextrin inclusion complexes and/or cyclodextrin derivative inclusion complex,
-randomly, the described at least a bioactivator of accepting to accept in the coating;
Described prosthese comprises the other seal coating that is deposited on the described matrix.
According to an embodiment, described prosthese comprises:
-the matrix that is made of porous materials,
-being applied to the coating that is used to accept bioactivator of described matrix, described coating comprises described at least a cyclodextrin and/or at least a cyclodextrin derivative and/or at least a cyclodextrin inclusion complexes and/or cyclodextrin derivative inclusion complex,
-randomly, the described at least a bioactivator of accepting to accept in the coating;
Described prosthese comprises the other seal coating that is deposited on the described matrix.
Do not want to be applied mechanism and fetter, cyclodextrin and/or cyclodextrin derivative and/or cyclodextrin inclusion complexes and/or cyclodextrin derivative inclusion complex are by reducing the ability of bacterial adhesion on armarium at least and working by the growth that reduces antibacterial subsequently.Therefore, cyclodextrin is given the antibacterial character of armarium even is given its bactericidal property.
Especially, in case armarium contacts for example 24 hours with blood plasma, the antibacterial or bactericidal action of being given by cyclodextrin promptly shows.Therefore, cyclodextrin and/or cyclodextrin derivative and/or cyclodextrin inclusion complexes and/or cyclodextrin derivative inclusion complex are preferably used for preparing and are used for the armarium that contacts with blood plasma or other biofluid or tissue, for example can be to the intravital equipment of the implanted patient of small part, when described armarium and blood plasma or other biofluid or tissue contact, particularly when in the implanted patient's body of part, will show its antibacterial or bactericidal property.
In this case, " antibacterial " is meant that material suppresses, stops or prevent the performance of bacterial community propagation.Bacteriostasis can maybe cannot mediate by the death of antibacterial.
In this case, " sterilization " be meant that material reduces or destroy the performance of bacterial community (passing through killing bacteria usually);
Prosthese of the present invention can be individually or is had one or more following features in the mode of technical feasible combination arbitrarily:
-described matrix has the chemical constitution that comprises hydroxy functional group and/or amine functional group, described structure
Covalently be attached on the described at least a cyclodextrin molecular of accepting coating or by the cyclodextrin group
On the polymer that becomes, its structure comprises the repeat pattern of following general formula:
Wherein, SB represents the chemical constitution of the matrix that the polymeric material by natural or artificial source forms, and X is oxygen atom or NH group, x＞3, and 2＜y＜(x-1) and (x-y)＞1,
-x is the number of the carboxyl functional group that polycarboxylic acids has before reaction,
-y represents the number of the carboxyl functional group of during reaction esterified or amidated polycarboxylic acids,
-(x-y) be the number that after reaction, does not have the carboxyl functional group of esterified or amidated polycarboxylic acids,
Wherein at least two carboxyl functional groups of expression following formula (COOH) have carried out esterification or esterification and amidation process respectively, and have had the polycarboxylic acids strand that at least one does not carry out the carboxyl functional group of esterification or amidation process
The molecular structure of-[CD] representative ring dextrin, described cyclodextrin is preferably selected from: alpha-cyclodextrin, beta-schardinger dextrin-, gamma-cyclodextrin and their mixture, their derivant is preferably selected from their amination derivant, the derivant that methylates, hydroxypropylation derivant, sulfo group butylation derivant, carboxyl methylation derivant or carboxy derivatives and their mixture; Described bioactivator is a therapeutic molecules at least a and cyclodextrin molecular and/or cyclodextrin derivative formation complex;
-described the coating of accepting is formed by the cross linked polymer of at least a cyclodextrin and/or the cross linked polymer of at least a cyclodextrin derivative and/or the cross linked polymer of at least a cyclodextrin inclusion complexes or cyclodextrin derivative inclusion complex, and its structure comprises the repeat pattern of following general formula:
Wherein, x＞3, and 2＜y≤(x-1) and (x-y) 〉=1,
-x is the number of the carboxyl functional group that polycarboxylic acids has before reaction,
-y represents the number of the carboxyl functional group of esterified polycarboxylic acids during reaction,
-(x-y) be the number that after reaction, does not have the carboxyl functional group of esterified polycarboxylic acids,
Wherein at least two carboxyl functional groups of expression following formula (COOH) have carried out esterification, and have had the polycarboxylic acids strand that at least one does not carry out the carboxyl functional group of esterification
The molecular structure of-[CD] representative ring dextrin, described cyclodextrin is preferably selected from: alpha-cyclodextrin, beta-schardinger dextrin-, gamma-cyclodextrin and their mixture, their derivant is preferably selected from their amination derivant, the derivant that methylates, hydroxypropylation derivant, sulfo group butylation derivant, carboxyl methylation derivant or carboxy derivatives and their mixture; Described bioactivator is the therapeutic molecules that forms complex with cyclodextrin molecular and/or cyclodextrin derivative;
-described porous material is by net, textile material or knit materials are made, described net, textile material or knit materials are formed by at least a polymer line, particularly on the basis that is selected from following polymer, form: polyethylene terephthalate (PET), polyethylene terephthalate ethylene glycol (PETG), polyurethanes (PU), polylactic acid, polyglycolic acid and copolymer thereof, polyvinylidene fluoride (PVDF), polytetrafluoroethylene (PTFE), Polyethylene Glycol (PEG), polyamide 6, polyamide 6,6, polypropylene, polyethylene and copolymer thereof, or the combination of these polymer;
-describedly accept the 5%-7% that coating forms described prosthese gross weight;
-described optional bioactivator is selected from anticoagulant, antithrombotic agent, antimitotic agent, antiproliferative, antitack agent, anti-migration agent, cell adhesion promoter, somatomedin, anti-parasitic molecule, antiinflammatory, antifungal, antimicrobial molecule, antiseptic and antibiotic;
-described matrix is carried out embossing;
-described seal coating maybe can seal at collagen, gelatin, polyurethanes on the basis of the polymer of described matrix or their combination and form.
-described matrix is a tubular matrix, and the described tubular matrix that provides described coating has defined the liquid circulation channel of sealing in inside;
By reading the embodiment in the following description and can better understand the present invention, wherein with reference to accompanying drawing:
Fig. 1 is the perspective side elevation view of first tubular prostheses of the present invention;
Fig. 2 is the sketch map of the first step of the method for preparation tubular prostheses of the present invention;
Fig. 3 is the view of the preparation method step that is similar to Fig. 2 after the step shown in Figure 2;
Fig. 4 is the view that is similar to Fig. 1 of second tubular prostheses of the present invention.
The present invention is applied to prosthese, the interior prosthese of blood vessel especially or has support straight or ramose tubular matrix.
First prosthese 10 of the present invention is shown in Fig. 1.As shown in the drawing, this prosthese comprises the embossing tubular matrix 12 that has the external coating 14 that is used to accept bioactivator and be used to seal the coating 16 of prosthese.
Described or each polymer line has defined a plurality of holes of extending by wall 18 between inner surface 20 and outer surface 24.Therefore tubular wall 18 is porous, does not have coating 14,16.
In the embodiment shown in fig. 1, wall 18 embossed or " becoming carinate ".Therefore, it has a plurality of annular ribs 26 to outer process.
Described coating 14,16 is applied on the line that forms wall 18 and is applied in the hole that is defined between the described line along inner surface 20 and outer surface 24.Described coating 14,16 combineds effect, to such an extent as to fill all holes basically, making provides the tubular matrix 12 of coating 14,16 has defined sealing with respect to X-X ' axle in inside blood circulation passage 22.
The coating 14 that is used to accept bioactivator comprises at least a cyclodextrin and/or cyclodextrin derivative and/or cyclodextrin inclusion complexes and/or cyclodextrin derivative inclusion complex.It also comprises polycarboxylic acids and catalyst.Described coating 14 is according at least a being attached on the tubular wall 18 in two kinds of associated methods of the following stated.
In first kind of associated methods, tubular wall 18 has the chemical constitution that comprises hydroxy functional group and/or amine functional group, described structure covalently be attached on the described at least a cyclodextrin molecular of accepting coating or the polymer formed by cyclodextrin on, its structure comprises the repeat pattern of following general formula:
Wherein, SB represents the chemical constitution of the tubular matrix that the polymeric material by natural or artificial source forms, and X is oxygen atom or NH group, x＞3, and 2＜y＜(x-1) and (x-y)＞1,
-x is the number of the carboxyl functional group that polycarboxylic acids has before reaction,
-y represents the number of the carboxyl functional group of during reaction esterified or amidated polycarboxylic acids,
-(x-y) be the number that after reaction, does not have the carboxyl functional group of esterified or amidated polycarboxylic acids,
Wherein at least two carboxyl functional groups of expression following formula (COOH) have carried out esterification or esterification and amidation process respectively, and have had the polycarboxylic acids strand that at least one does not carry out the carboxyl functional group of esterification or amidation process
The molecular structure of-[CD] representative ring dextrin, described cyclodextrin is preferably selected from: alpha-cyclodextrin, beta-schardinger dextrin-, gamma-cyclodextrin and their mixture;
In this case, obtain described coating by forming the polycarboxylic acids anhydride, described polycarboxylic acids anhydride reacts with described material by form amide or ester type covalent bond between material that forms tubular wall 18 and polycarboxylic acids.Under the simplest situation, form second polycarboxylic acid anhydride be attached on the described material and with cyclodextrin molecular or be fixed on cyclodextrin molecular reaction in the ester bond with cyclodextrin molecular or cyclodextrin derivative.
In second kind of associated methods, the described coating of accepting is formed by the cross linked polymer of at least a cyclodextrin and/or the cross linked polymer of at least a cyclodextrin derivative and/or the cross linked polymer of at least a cyclodextrin inclusion complexes or cyclodextrin derivative inclusion complex, and its structure comprises the repeat pattern of following general formula:
Wherein, x＞3, and 2＜y≤(x-1) and (x-y) 〉=1,
-x is the number of the carboxyl functional group that polycarboxylic acids has before reaction,
-y represents the number of the carboxyl functional group of esterified polycarboxylic acids during reaction,
-(x-y) be the number that after reaction, does not have the carboxyl functional group of esterified polycarboxylic acids,
Wherein at least two carboxyl functional groups of expression following formula (COOH) have carried out esterification, and have had the strand of the polycarboxylic acids of at least one carboxyl functional group that does not carry out esterification
The molecular structure of-[CD] representative ring dextrin, described cyclodextrin is preferably selected from: alpha-cyclodextrin, beta-schardinger dextrin-, gamma-cyclodextrin and their mixture;
In the second approach, the cross linked polymer that described or each cyclodextrin and/or cyclodextrin derivative are formed is fixed, and described cross linked polymer obtains by the exclusive reaction (exclusive reaction) between cyclodextrin molecular and/or cyclodextrin derivative and at least a polycarboxylic acids.The cross linked polymer that forms thus forms film or is deposited on the surface of line of tubular wall 18 or is deposited over the inside of its loose structure and for good and all is fixed on the there.
In variant, coexist two kinds of associated methods on the line that forms wall 18.
In this embodiment, by being deposited on collagenic coating on the line that forms tubular wall 18, defining the collagenic coating in the hole between the line and forming described seal coating 16 at the collagenic coating of accepting on the coating 14.Collagen has formed the film of the opening between sealing inner surface 20 and the outer surface 24, thereby has formed the seal channel 22 in tubular matrix 12 inside.
In variant, described seal coating 16 maybe can seal at gelatin, polyurethanes on the basis of any other polymer of described tubular matrix 12 or their mixture and form.
Optional bioactivator is accepted by the hollow molecules structure that is formed by each cyclodextrin.Described bioactivator is selected from anticoagulant, antithrombotic agent, antimitotic agent, antiproliferative, antitack agent, anti-migration agent, cell adhesion promoter, somatomedin, anti-parasitic molecule, antiinflammatory, short angiogenic agent, angiogenesis inhibitor, vitamin, hormone, protein, antifungal, antimicrobial molecule, antiseptic or antibiotic.
2 and 3 the method for preparing prosthese 10 of the present invention is described with reference to the accompanying drawings.
This method comprises the step 40 with tubular matrix 12 molding, applies the step 42 of accepting coating 14, and neutralization procedure 43 applies the step 44 of seal coating 16, then, randomly, loads the step 46 of bioactivators to prosthese 10.
In the beginning of forming step 40, provide polymer line base net, weaving or knitting tubular matrix 12.Described tubular matrix 12 begins to have slick outer surface 24 and slick inner surface 20 and porous tubular wall 18 most.
Then, will form described tubular wall 18 embossing of matrix to form rib 26.
The step 42 that applies coating 14 comprise with each become mold base 12 immerse in the solution 52 of 50 precursor mixtures, with the precuring 56 of the filling (padding) 54 of each matrix 12 of precursor mixture dipping, each matrix 12, solidify 58 and washing and dry 60.
-at least a cyclodextrin and/or at least a cyclodextrin derivative and/or at least a cyclodextrin inclusion complexes and/or cyclodextrin derivative inclusion complex,
-at least a polycarboxylic acids, and
-optional catalyst;
Described cyclodextrin is preferably selected from: alpha-cyclodextrin, beta-schardinger dextrin-, gamma-cyclodextrin and their mixture; Their derivant is preferably selected from the amination derivant of these cyclodextrin, the derivant that methylates, hydroxypropylation derivant, sulfo group butylation derivant, carboxyl methylation derivant or carboxy derivatives and their mixture.
Described carboxylic acid is selected from saturated and unsaturated acyclic polycarboxylic acids, saturated and unsaturated cyclic polycarboxylic acids, aromatics polycarboxylic acids, hydroxyl polycarboxylic acids, optimization citric acid, polyacrylic acid, polymethylacrylic acid, 1,2,3,4-BTCA, maleic acid, citraconic acid, itaconic acid, 1,2, the 3-tricarballylic acid, anti--equisetic acid, complete-suitable-1,2,3,4-Pentamethylene. tetrabasic carboxylic acid, mellic acid., oxo disuccinic acid, sulfo-disuccinic acid or be selected from anhydride derived from described carboxylic acid.
Described catalyst is selected from alkali metal salt, carbonate, bicarbonate, acetate, borate, alkali metal hydroxide, aliphatic amine and the ammonia of dihydric phosphate, hydrophosphate, phosphate, hypophosphites, alkali metal phosphite, polyphosphoric acid; Be preferably selected from dibastic sodium phosphate, sodium dihydrogen phosphate and sodium hypophosphite.
Described mixture is preferably formed by polycarboxylic acids, catalyst and the cyclodextrin amount with following weight: polycarboxylic acids: 2-4, and catalyst: 1, cyclodextrin: 2-5.
By making the tubular matrix 12 that is impregnated with precursor mixture by clogging 54 between two rollers 62 and by tubular matrix 12 is remained between the roller 62.
Heating steps carried out 1-90 minute in temperature is 100-220 ℃ stove 64.
Based on the gross weight of prosthese after the drying 10, the retention rate of accepting coating 14 is 5%-7%.This retention rate has kept the physics of prosthese 10 and engineering properties for example elasticity, anti-piercing through property and pliability.
In neutralization procedure 43, each tubular matrix 12 is dropped into basic carbonates for example in the aqueous solution of sodium carbonate.
The concentration of this solution is 1g/l-5g/l.The soak time of each tubular matrix 12 in neutralization solution is for example 1-60 minute.
After only providing prosthese 10 bone dries of accepting coating 14, use Soxhlet (soxhlet) device water to carry out washing step 72 3 times.Therefore, the pH of inner surface and outer surface equals 7 substantially.
The step 44 that applies collagenic coating comprises tubular matrix 12 is immersed in the aqueous solution of 74 collagens 76.Collagen for example is selected from the IV Collagen Type VI available from Corii Bovis seu Bubali.Collagen concentration in the solution is 2 weight %-4 weight %.Based on the dry back gross weight of the matrix 12 that provides the coating 14,16 that forms prosthese 10, the retention rate of collagen on matrix 12 is for example 20 weight %-30 weight %.
Collagen for example is to provide on the basis of the aqueous solution with acid pH, is provided by the SYMATHESE of French company.Glycerol is joined in the collagen solution improving resilience, and add entry, that is, be about 7 pH so that collagen solution is adjusted to neutral pH.
Then with prosthese 10 dryings 78.Use the ionization beta rays with prosthese 10 sterilizations subsequently.
When implementing, the step 46 that prosthese 10 is loaded active ingredient can for example be undertaken by the surgeon before being about to operation.Subsequently prosthese 10 is dropped into and contain in the bath 80 of bioactivator.Described bioactivator is selected from anticoagulant, antithrombotic agent, antimitotic agent, antiproliferative, antitack agent, anti-migration agent, cell adhesion promoter, somatomedin, anti-parasitic molecule, antiinflammatory, short angiogenic agent, angiogenesis inhibitor, vitamin, hormone, protein, antifungal, antimicrobial molecule, antiseptic or antibiotic.
The feasible prosthese that can obtain advantageously to be loaded with bioactivator of said method, described bioactivator discharges after implanted human body in vivo gradually.
The cooperation that is used to accept the coating 14 of active ingredient and seal coating 16 makes and can obtain the prosthese that the mode with extremely safe with regard to its implant into body seals.The use amount of part cooperation reduction collagen of coating 14,16 provides the sealing of good level simultaneously, and this has limited the risk relevant with there being animal collagen.
Unexpectedly, the existence of seal coating 16 does not influence accepts the ability that coating 16 loads bioactivators, in case also not in the influence implant into body its with the dispersive ability of this bioactivator.
Optimize the amount of accepting coating 14 and seal coating 16 that is deposited on the tubular matrix 12, so that good physics and engineering properties (resilience, anti-piercing through property, impermeability, pliability etc.) to be provided.
And, with regard to subsequently with prosthese implant into body and blood with regard to the intravital circulation of vacation, the blood compatibility that provides coated 14,16 walls 18 that cover with the inner surface 20 and outer surface 24 neutralizations of prosthese 10.
The existence of embossing has further improved and has accepted the adhesion of coating 14 at the inner surface 20 and the outer surface 24 of prosthese 14 on the prosthese 10, this reduced again precursor mixture solution 52 concentration and avoided fold or folding.
Therefore inner surface 20 forms first surface, and described first surface separates with the second surface that is formed by outer surface 24 in the mode of sealing, and simultaneously, matrix 12 provides coating 14,16.
In another variant, matrix 12 is formed by the assembly of non-textile polymer fiber, and described non-textile fiber is bonded to each other, and for example is bonded to each other by binding agent.
In another variant, prosthese is the vascular repair sheet (vascularpatch) that comprises the matrix 12 of non-tubular shape.Therefore this matrix 12 is planar basically and has less than the nominal wall thickness of 0.6mm and the tolerance horizontal stitching (suture) more than or equal to 15N.Therefore this matrix 12 has defined by coating 14,16 is isolated in the mode of sealing and has been planar upper surface substantially and is planar lower surface substantially.
Another advantage of the present invention relates to the ability that coating is accepted bioactivator, and described coating comprises cyclodextrin and/or cyclodextrin derivative and/or cyclodextrin inclusion complexes.
In fact, the prosthese that applicant's discovery comprises based on the above-mentioned type of cyclodextrin and/or cyclodextrin derivative and/or cyclodextrin inclusion complexes shows bacteriostatic activity, but described coating is not to be impregnated with bioactivator.
With respect to the contrast that does not have based on the coating prosthese of cyclodextrin and/or cyclodextrin derivative and/or cyclodextrin inclusion complexes, cyclodextrin or derivatives thereof or the distinctive bacteriostatic activity of cladding compound highly significant in the bacterial adhesion experiment.
In following prosthese and embodiment that blood plasma contacts, introduce the evidence of these character in detail.
These results have shown that at least a cyclodextrin of use and/or cyclodextrin derivative and/or cyclodextrin inclusion complexes are used to prepare antibacterial armarium, even more advantages of sterilization armarium, and described equipment is implantable prosthesis or biomaterial particularly.
Such equipment is for example blood vessel prosthesis or vascular repair sheet, stitching thread, dialysis catheter, perfusion cannula, artificial nutrition conduit, implantable catheter lumen, stomodaeal valve, crown support, exposed or cover periphery support, the chest endoprosthesis, drainage tube, dental implants, wall reinforcement material (hernia/alvus is outstanding), the percutaneous implant, guide tissue regeneration film, guiding bore regenerating film, loosening all muscles equipment, the grid of organizational project and network, micropore and macropore skeleton sub, the dressing that medical treatment and veterinary use.
Embodiment: shown cyclodextrin and/or cyclodextrin derivative and/or the distinctive bacteriostatic activity of cyclodextrin inclusion complexes coating
Estimated the cyclodextrin coating to the influence of bacterial adhesion to the ability of tubular prostheses of the present invention.
For this purpose, on two types blood vessel prosthesis, carry out the bacterial adhesion test:
-" cycloD PMC " blood vessel prosthesis is formed by weaving or the tubular portion made of knitting polyester, be coated with collagen (15%p/p) and HPB cyclodextrin (hydroxypropyl-beta-schardinger dextrin-, 15%p/p).
-" PMC " blood vessel prosthesis, the tubular portion of being made by weaving or knitting polyester forms, and is coated with collagen (30%p/p).
Prepare the disk that diameter is 1cm from cycloD PMC or PMC blood vessel prosthesis.
Under 37 ℃, each four of cycloD PMC and PMC prostheses are immersed in the blood plasma of 12ml 24 hours respectively, stir simultaneously.
All disks of flushing in DPBS buffer (Dulbecco ' s phosphate buffer) then.
Then two disks of every kind of prosthese are immersed in the bacterial suspension (10 of staphylococcus aureus (Staphyloccocusaureus) (ATCC 6538) or bacillus pyocyaneus (Pseudomonas aerugenosa) (ATC 9027)
4UFC/ml) in 1 hour, then with the flushing of DPBS buffer (two disks of the corresponding every kind of prosthese of each bacterial strain).
Collect antibacterial according to following scheme from disk then:
-under ambient temperature (+15-25 ℃) with the frequency sonic oscillation of 47KHz ± 6% 5 minutes;
-under ambient temperature (+15-25 ℃) with the speed mechanical agitation of 800rpm 20 minutes;
-eddy current stirred 30 seconds under ambient temperature (+15-25 ℃).
Then with extract from 10
-1Be diluted to 10
-3, and filter with the defecator of 0.45 μ m.Under 30-35 ℃ temperature and the aerobic conditions with the film collected incubation 24 hours on the tryptose soya agar flat board.
Naked eyes are measured the bacterium colony number.
The gained result is as shown in table 1 below.
Table 1: from blood plasma in advance incubation the microbe number collected of 24 hours disk
ND: undetermined
Incubation was coated with white felt sample layer with the PMC prosthese after 24 hours in blood plasma, removed described white felt sample layer subsequently.
Soak after 24 hours in blood plasma, the bacterial adhesion of observing the PMC blood vessel prosthesis exceeds more than 2log with respect to CyloD PMC prosthese, proves that thus the cyclodextrin coating has reduced the ability of bacterial adhesion.
These results show and comprise:
(i) porous material parent tube shape matrix 12; The coating 14 that (ii) comprises at least a cyclodextrin and/or at least a cyclodextrin derivative and/or at least a cyclodextrin inclusion complexes and/or cyclodextrin derivative inclusion complex; (iii) other seal coating 16; Implantable tubular prostheses constituted antibacterial, even germ-resistant implantable tubular prostheses.The test of the bactericidal effect relevant with the cyclodextrin coating is underway at present.
Therefore such prosthese is particularly advantageous, even because for example the cyclodextrin coating is not impregnated with antibiotic or bioactivator, they have still reduced the infection risk of postoperative.
Claims (25)
1, prepare the method for implantable prosthesis (10) from the matrix (12) that is made of porous materials, described method comprises following consecutive steps:
A) apply the coating (14) that (50) are used to accept bioactivator to matrix (12), the described coating (14) of accepting comprising:
-at least a cyclodextrin and/or at least a cyclodextrin derivative and/or at least a cyclodextrin inclusion complexes and/or cyclodextrin derivative inclusion complex,
-at least a polycarboxylic acids, and
-optional catalyst;
B) with the temperature of described matrix (12) heating (58), heated 1-90 minute to 100 ℃-220 ℃;
C) washing (60) described matrix (12) in water;
D) with described matrix (12) drying; Then
E) randomly, described matrix (12) is immersed in the concentrated solution of (46) at least a bioactivator;
It is characterized in that described method goes up the step (44) that deposits other seal coating (16) at described matrix (12) after being included in drying steps.
2, the method for claim 1 is characterized in that, described seal coating (16) maybe can seal at collagen, gelatin, polyurethanes on the basis of the polymer of described matrix (12) or their combination and form.
3, method as claimed in claim 1 or 2 is characterized in that, comprises described matrix is immersed in the aqueous solution (52) in applying the step (50) of accepting coating (14), and described aqueous solution comprises:
-at least a cyclodextrin and/or at least a cyclodextrin derivative and/or at least a cyclodextrin inclusion complexes and/or cyclodextrin derivative inclusion complex,
-at least a polycarboxylic acids, and
-optional catalyst.
4, as the described method of one of claim 1-3, it is characterized in that, its be included in heating steps (58) before under 40 ℃-100 ℃ temperature with the step (56) of described matrix precuring (12).
5, the described method of one of claim as described above is characterized in that it is included in the step (43) that drying steps (60) is neutralized to described matrix (12) neutral pH afterwards.
6, the described method of one of claim as described above, it is characterized in that, described matrix (12) is by assembly, net, textile material or knit materials are made, described assembly, net, textile material or knit materials are formed by at least a polymer line, particularly on the basis that is selected from following polymer, form: polyethylene terephthalate (PET), polyethylene terephthalate ethylene glycol (PETG), polyurethanes (PU), polylactic acid, polyglycolic acid and copolymer thereof, polyvinylidene fluoride (PVDF), polytetrafluoroethylene (PTFE), Polyethylene Glycol (PEG), polyamide 6, polyamide 6,6, polypropylene, polyethylene and copolymer thereof, or the combination of these polymer.
7, the described method of one of claim as described above is characterized in that, describedly accepts the 5%-7% that coating (14) forms the gross weight of described prosthese (10).
8, the described method of one of claim as described above is characterized in that, it comprises described matrix (12) is immersed step e) in the concentrated solution of (46) at least a bioactivator.
9, method as claimed in claim 8, it is characterized in that described bioactivator is selected from anticoagulant, antithrombotic agent, antimitotic agent, antiproliferative, antitack agent, anti-migration agent, cell adhesion promoter, somatomedin, anti-parasitic molecule, antiinflammatory, short angiogenic agent, angiogenesis inhibitor, vitamin, hormone, protein, antifungal, antimicrobial molecule, antiseptic or antibiotic.
10, the described method of one of claim as described above is characterized in that, its be included in apply accept coating (14) step (50) before and/or after washing step with the step (40) of matrix (12) embossing.
11, the described method of one of claim as described above is characterized in that described matrix (12) is a tubular matrix, and the described tubular matrix (12) that provides described coating (14,16) has defined the liquid circulation channel (22) of sealing in inside.
12, implantable prosthesis (10), it comprises
-the matrix (12) that is made of porous materials,
-be applied to the coating that is used to accept bioactivator (14) of described matrix (12), described coating comprises at least a cyclodextrin and/or at least a cyclodextrin derivative and/or at least a cyclodextrin inclusion complexes and/or cyclodextrin derivative inclusion complex
-randomly, the described at least a bioactivator of accepting acceptance in the coating (14);
It is characterized in that described prosthese (10) comprises the other seal coating (16) that is deposited on the described matrix (12).
13, prosthese as claimed in claim 12, it is characterized in that, described matrix (12) has the chemical constitution that comprises hydroxy functional group and/or amine functional group, described structure covalently be attached on the described at least a cyclodextrin molecular of accepting coating or the polymer formed by cyclodextrin on, its structure comprises the repeat pattern of following general formula:
Wherein, SB represents the chemical constitution of the described matrix that the polymeric material by natural or artificial source forms, and X is oxygen atom or NH group, x＞3, and 2＜y＜(x-1) and (x-y)＞1,
-x is the number of the carboxyl functional group that polycarboxylic acids has before reaction,
-y represents the number of the carboxyl functional group of during reaction esterified or amidated polycarboxylic acids,
-(x-y) be the number that after reaction, does not have the carboxyl functional group of esterified or amidated polycarboxylic acids,
Wherein at least two carboxyl functional groups of expression following formula (COOH) have carried out esterification or esterification and amidation process and have the polycarboxylic acids strand that at least one does not carry out the carboxyl functional group of esterification or amidation process respectively
The molecular structure of-[CD] representative ring dextrin, described cyclodextrin is preferably selected from: alpha-cyclodextrin, beta-schardinger dextrin-, gamma-cyclodextrin and their mixture, their derivant, be preferably selected from their amination derivant, the derivant that methylates, hydroxypropylation derivant, sulfo group butylation derivant, carboxyl methylation derivant or carboxy derivatives, and their mixture; Described bioactivator is a therapeutic molecules at least a and cyclodextrin molecular and/or cyclodextrin derivative formation complex.
14, as claim 12 or 13 described prostheses (10), it is characterized in that, the described coating (14) of accepting is formed by the cross linked polymer of at least a cyclodextrin and/or the cross linked polymer of at least a cyclodextrin derivative and/or the cross linked polymer of at least a cyclodextrin inclusion complexes or cyclodextrin derivative inclusion complex, and its structure comprises the repeat pattern of following general formula:
Wherein, x＞3, and 2＜y≤(x-1) and (x-y) 〉=1,
-x is the number of the carboxyl functional group that polycarboxylic acids has before reaction,
-y represents the number of the carboxyl functional group of esterified polycarboxylic acids during reaction,
-(x-y) be the number that after reaction, does not have the carboxyl functional group of esterified or amidated polycarboxylic acids,
Wherein at least two carboxyl functional groups of expression following formula (COOH) have carried out esterification and have the polycarboxylic acids strand that at least one does not carry out the carboxyl functional group of esterification
The molecular structure of-[CD] representative ring dextrin, described cyclodextrin is preferably selected from: alpha-cyclodextrin, beta-schardinger dextrin-, gamma-cyclodextrin and their mixture, their derivant is preferably selected from their amination derivant, the derivant that methylates, hydroxypropylation derivant, sulfo group butylation derivant, carboxyl methylation derivant or carboxy derivatives and their mixture; Described bioactivator is the therapeutic molecules that forms complex with cyclodextrin molecular and/or cyclodextrin derivative.
15, as the described prosthese of one of claim 12-14 (10), it is characterized in that, described porous material is by assembly, net, textile material or knit materials are made, described assembly, net, textile material or knit materials are formed by at least a polymer line, particularly on the basis that is selected from following polymer, form: polyethylene terephthalate (PET), polyethylene terephthalate ethylene glycol (PETG), polyurethanes (PU), polylactic acid, polyglycolic acid and copolymer thereof, polyvinylidene fluoride (PVDF), polytetrafluoroethylene (PTFE), Polyethylene Glycol (PEG), polyamide 6, polyamide 6,6, polypropylene, polyethylene and copolymer thereof, or the combination of these polymer.
16, as the described prosthese of one of claim 12-15 (10), it is characterized in that, describedly accept the 5%-7% that coating (14) forms the gross weight of described prosthese (10).
As the described prosthese of one of claim 12-16 (10), it is characterized in that 17, it comprises at least a bioactivator of accepting acceptance in the coating (14).
18, as the described prosthese of one of claim 12-17 (10), it is characterized in that described bioactivator is selected from anticoagulant, antithrombotic agent, antimitotic agent, antiproliferative, antitack agent, anti-migration agent, cell adhesion promoter, somatomedin, anti-parasitic molecule, antiinflammatory, antifungal, antimicrobial molecule, antiseptic and antibiotic.
As the described prosthese of one of claim 12-18 (10), it is characterized in that 19, described seal coating (16) maybe can seal at collagen, gelatin, polyurethanes on the basis of the polymer of described matrix (12) or their combination and form.
As the described prosthese of one of claim 12-19 (10), it is characterized in that 20, described matrix (12) is a tubular matrix, the described tubular matrix (12) that provides described coating (14,16) has defined the liquid circulation channel (22) of sealing in inside.
21, at least a cyclodextrin and/or at least a cyclodextrin derivative and/or at least a cyclodextrin inclusion complexes and/or the cyclodextrin derivative inclusion complex application in preparation biocidal property armarium (10).
22, application as claimed in claim 21, it is to be used to prepare bactericidal properties armarium (10).
23, as claim 21 or 22 described application, it is characterized in that, described armarium (10) be used for blood plasma or arbitrarily other biofluid or the tissue contact.
24, as the described application of one of claim 21-23, it is characterized in that, described armarium (10) can implanted at least in part patient's body in.
25, as claim 21 or 24 described application, wherein said equipment (10) is implantable prosthesis, and it comprises:
-the matrix (12) that is made of porous materials,
-be applied to the coating that is used to accept bioactivator (14) on the described matrix (12), described coating comprises described at least a cyclodextrin and/or at least a cyclodextrin derivative and/or at least a cyclodextrin inclusion complexes and/or cyclodextrin derivative inclusion complex
-randomly, the described at least a bioactivator of accepting acceptance in the coating (14); Described prosthese (10) comprises the other seal coating (16) that is deposited on the described matrix (12).
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0609678A FR2908047B1 (en) | 2006-11-06 | 2006-11-06 | PROCESS FOR PREPARING AN IMPLANTABLE TUBULAR PROSTHESIS FROM A BASIC TUBULAR BODY OF POROUS MATERIAL, AND ASSOCIATED PROSTHESIS |
| FR0609678 | 2006-11-06 | ||
| FR0758629 | 2007-10-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101573149A true CN101573149A (en) | 2009-11-04 |
Family
ID=38051568
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2007800450001A Pending CN101573149A (en) | 2006-11-06 | 2007-11-05 | Method for preparing an implantable prosthesis from a porous base body and associated prosthesis and use thereof |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN101573149A (en) |
| FR (1) | FR2908047B1 (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017140152A1 (en) * | 2016-02-15 | 2017-08-24 | 丹阳纳瑞康纳米科技有限公司 | Vascular scaffold containing combined drug coating |
| CN111511414A (en) * | 2017-10-31 | 2020-08-07 | 豪淘斯医疗有限公司 | Textile product with sealant or coating and method of manufacture |
| CN112472877A (en) * | 2020-12-18 | 2021-03-12 | 南京鼓楼医院 | Method for preparing lubricating oil-infused ultra-smooth porous surface for medical catheter |
| US11577003B2 (en) | 2017-10-31 | 2023-02-14 | Hothouse Medical Limited | Textile products having selectively applied sealant or coating with visual indicator and method of detecting the same |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8541047B1 (en) * | 2008-03-24 | 2013-09-24 | Richard J. Shaw | Polar antiseptic/antibacterial containing toothpick probes |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5405378A (en) * | 1992-05-20 | 1995-04-11 | Strecker; Ernst P. | Device with a prosthesis implantable in the body of a patient |
| DE19849464A1 (en) * | 1997-04-30 | 2000-04-27 | Schering Ag | Stent with polymeric coating having pockets, preferably cyclodextrin stuctures, containing active agent for prophylaxis of restenosis |
| FR2789685B1 (en) * | 1999-02-15 | 2001-05-04 | Univ Lille Sciences Tech | PROCESS FOR MANUFACTURING SOLUBLE AND INSOLUBLE POLYMERS BASED ON CYCLODEXTRIN (S) AND / OR DERIVATIVES OF CYCLODEXTRIN (S) AND SOLUBLE POLYMERS BASED ON CYCLODEXTRIN (S) AND / OR DERIVATIVES OF CYCLODEXTRIN (S) |
| FR2789704B1 (en) * | 1999-02-15 | 2003-09-26 | Univ Lille Sciences Tech | METHOD FOR TREATING A FIBER OR FIBER-BASED MATERIAL IN ORDER TO IMPROVE ITS ADSORBENT PROPERTIES AND FIBER OR FIBER-BASED MATERIAL HAVING IMPROVED ADSORBENT PROPERTIES |
| US20060058867A1 (en) * | 2004-09-15 | 2006-03-16 | Thistle Robert C | Elastomeric radiopaque adhesive composite and prosthesis |
| FR2877846B1 (en) * | 2004-11-15 | 2008-12-05 | Univ Lille Sciences Tech | BIOMATERIAL CARRIERS OF CYCLODEXTRINS WITH IMPROVED ABSORPTION PROPERTIES AND PROGRESSIVE AND DELAYED RELEASE OF THERAPEUTIC MOLECULES |
-
2006
- 2006-11-06 FR FR0609678A patent/FR2908047B1/en not_active Expired - Fee Related
-
2007
- 2007-11-05 CN CNA2007800450001A patent/CN101573149A/en active Pending
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017140152A1 (en) * | 2016-02-15 | 2017-08-24 | 丹阳纳瑞康纳米科技有限公司 | Vascular scaffold containing combined drug coating |
| CN111511414A (en) * | 2017-10-31 | 2020-08-07 | 豪淘斯医疗有限公司 | Textile product with sealant or coating and method of manufacture |
| US11577003B2 (en) | 2017-10-31 | 2023-02-14 | Hothouse Medical Limited | Textile products having selectively applied sealant or coating with visual indicator and method of detecting the same |
| US11666683B2 (en) | 2017-10-31 | 2023-06-06 | Hothouse Medical Limited | Textile products having a sealant or coating and method of manufacture |
| CN112472877A (en) * | 2020-12-18 | 2021-03-12 | 南京鼓楼医院 | Method for preparing lubricating oil-infused ultra-smooth porous surface for medical catheter |
| CN112472877B (en) * | 2020-12-18 | 2022-03-08 | 南京鼓楼医院 | Method for preparing lubricating oil-infused ultra-smooth porous surface for medical catheter |
Also Published As
| Publication number | Publication date |
|---|---|
| FR2908047A1 (en) | 2008-05-09 |
| FR2908047B1 (en) | 2009-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2327492T3 (en) | ANTIMICROBIAL MEDICAL DEVICES. | |
| JP5329090B2 (en) | Biomaterials with cyclodextrin with improved absorption properties for sustained and delayed release of therapeutic molecules | |
| US7803574B2 (en) | Medical device applications of nanostructured surfaces | |
| US7972616B2 (en) | Medical device applications of nanostructured surfaces | |
| EP1781210B1 (en) | Composite vascular graft including bioactive agent coating and biodegradable sheath | |
| JPH0924093A (en) | Grafting body, its application during surgical operation, and its preparation | |
| JP2012125575A (en) | Medical device intended to come in contact with patient's tissue and related manufacturing method | |
| JP2001501516A (en) | Coated prosthetic heart valve | |
| JP2008507333A (en) | Composite vascular graft with bioactive agent | |
| CN101573149A (en) | Method for preparing an implantable prosthesis from a porous base body and associated prosthesis and use thereof | |
| US20040171323A1 (en) | Antimicrobial, synthetic, fibrous, and tubular medical divices | |
| JP2016520361A5 (en) | ||
| JP2010508109A (en) | Method for producing an implantable prosthesis from a base element made of a porous material, a prosthesis related thereto and use thereof | |
| JP5275583B2 (en) | Medical materials and manufacturing method thereof | |
| Desgrandchamps et al. | The artificial bladder | |
| AU2014336244B2 (en) | PGA tubular patch and relative optional tubular support made of absorbable material for the tissue reconstruction of urethral and/or ureteral removed segments | |
| Chen et al. | Antimicrobial textiles for sutures, implants, and scaffolds | |
| JPH0636820B2 (en) | Mandrill graft insertion method | |
| Gupta et al. | Polyester and nylon based textiles in biomedical engineering | |
| OA17687A (en) | PGA tubular patch and relative optional tubular support made of absorbable material for the tissue reconstruction of urethral and/or ureteral removed segments. | |
| FR2922774A1 (en) | Making an implantable prosthesis from a porous material based tubular body, comprises applying a reception coating of a bioactive agent, heating, washing, drying and impregnating in a solution concentrated with a bioactive agent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20091104 |